Cargando…

The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention

The optimal antiplatelet therapy after percutaneous coronary intervention (PCI) remains to be elucidated. Monotherapy with a P2Y12 inhibitor may be inferior to dual antiplatelet therapy in patients after PCI. PubMed, EMBASE (by Ovidsp), Web of Science, and The Cochrane Library were searched from dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Liman, Fu, Menglu, Li, Yuanyuan, Chen, Zhihui, Yu, Jing, Luo, Jinlan, Hu, Shuiqing, Tu, Ling, Xu, Xizhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068072/ https://www.ncbi.nlm.nih.gov/pubmed/31777973 http://dx.doi.org/10.1002/clc.23305

Ejemplares similares

The potential association between common comorbidities and severity and mortality of coronavirus disease 2019: A pooled analysis
por: Luo, Liman, et al.
Publicado: (2020)

Inhibition of soluble epoxide hydrolase alleviates insulin resistance and hypertension via downregulation of SGLT2 in the mouse kidney
por: Luo, Jinlan, et al.
Publicado: (2021)

sEH Inhibitor Tppu Ameliorates Cecal Ligation and Puncture-Induced Sepsis by Regulating Macrophage Functions
por: Chen, Zhihui, et al.
Publicado: (2020)

P2Y(12) Inhibitor Monotherapy after Percutaneous Coronary Intervention
por: Zhou, Xuan, et al.
Publicado: (2022)

P2Y12 blocker monotherapy after percutaneous coronary intervention
por: Verheugt, F. W. A., et al.
Publicado: (2021)

Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
por: Feng, Wen-Han, et al.
Publicado: (2022)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020)

P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
por: Feng, Wen-Han, et al.
Publicado: (2023)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis
por: Zhang, Wen-bin, et al.
Publicado: (2021)

P2Y(12) inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial
por: Roh, Ji Woong, et al.
Publicado: (2021)

P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
por: Sotomi, Yohei, et al.
Publicado: (2023)

Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
por: Shin, Eun-Seok, et al.
Publicado: (2023)

P2y(12) inhibitor monotherapy after 1–3 months dual antiplatelet therapy in patients with coronary artery disease and chronic kidney disease undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials
por: Yu, Yanqiao, et al.
Publicado: (2023)

Efficacy and safety of potent P2Y12 inhibitors vs. clopidogrel in elderly patients with acute coronary syndrome
por: Luo, Li-Man, et al.
Publicado: (2020)

EETs reduces LPS-induced hyperpermeability by targeting GRP78 mediated Src activation and subsequent Rho/ROCK signaling pathway
por: Dong, Ruolan, et al.
Publicado: (2017)

Intolerance to Multiple P2Y12 Inhibitors Following Percutaneous Coronary Intervention
por: Shnoda, Mina, et al.
Publicado: (2021)

De-escalation of P2Y12 Inhibitor Use After Percutaneous Coronary Intervention and Acute Coronary Syndromes
por: Barry, Quinton, et al.
Publicado: (2021)

Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2023)

Age-related changes in mineralocorticoid receptors in rat hearts
por: Hu, Danli, et al.
Publicado: (2020)

Endothelium‐specific CYP2J2 overexpression attenuates age‐related insulin resistance
por: Yang, Yan, et al.
Publicado: (2018)

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention
por: Vergara-Jimenez, Jennifer, et al.
Publicado: (2010)

The safety of Ramadan Fasting following Percutaneous Coronary Intervention
por: Amin, Osama A., et al.
Publicado: (2020)

Safety of clinical engineer-assisted percutaneous coronary intervention
por: Oguri, Mitsutoshi, et al.
Publicado: (2022)

Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients
por: Kim, Dong-Yeon, et al.
Publicado: (2021)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Selection of percutaneous coronary intervention in elderly patients with acute myocardial infarction in tertiary hospital
por: Chen, Liwei, et al.
Publicado: (2019)

Cost-Effectiveness of Clopidogrel vs Aspirin Monotherapy After Percutaneous Coronary Intervention: Results From the HOST-EXAM Study
por: Hwang, Doyeon, et al.
Publicado: (2023)

Safety and feasibility of robotic assisted percutaneous coronary intervention compared to standard percutaneous coronary intervention- a systematic review and meta-analysis
por: Tripathi, Byomesh, et al.
Publicado: (2021)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

Multifaceted Intervention to Improve P2Y12 Inhibitor Adherence After Percutaneous Coronary Intervention: A Stepped Wedge Trial
por: Ho, P. Michael, et al.
Publicado: (2022)

Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention
por: Centurión, Osmar Antonio
Publicado: (2016)

Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort
por: Obayashi, Yuki, et al.
Publicado: (2022)

De-Escalation of P2Y(12) Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention
por: Kupka, Danny, et al.
Publicado: (2018)

Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
por: Kumar, Arun, et al.
Publicado: (2022)

Telephone-based reminder to improve safety after percutaneous coronary intervention
por: Chidester, Jeffrey, et al.
Publicado: (2022)

P2Y(12) Platelet Receptors: Importance in Percutaneous Coronary Intervention
por: Falcão, Felipe Jose de Andrade, et al.
Publicado: (2013)

Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Liu, Xiao-Qiang, et al.
Publicado: (2020)

Safety and efficacy of the Expressman Extension System for complex coronary lesions during percutaneous coronary intervention
por: Ma, Yanzhuo, et al.
Publicado: (2023)

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_1dujpnc4a2euta9bdl7v2h05bv